Background Understanding the evolving treatment patterns in patients with rheumatoid
arthritis (RA) is important for rheumatologists to make the best practice decisions and …

Objectives To describe the illness perceptions of patients with RA over the first year of MTX
treatment, and the association between illness perceptions and outcomes. Methods Data …

Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action
from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein …

Objectives Clinical trials have shown a beneficial effect from biological disease-modifying
antirheumatic drugs (bDMARDs) on hand or axial bone loss in patients with rheumatoid …

Objectives To quantify tolerance to risks of preventive treatments among first-degree
relatives (FDRs) of patients with rheumatoid arthritis (RA). Methods Preventive treatments for …

Objectives Treatment non-adherence is more frequent among difficult-to-treat (D2T) than
among non-D2T RA patients. Perceptions of non-adherence may differ. We aimed to …

Rheumatoid arthritis is one of the most prevalent musculoskeletal disorders that, when
insufficiently treated, results in detrimental sequelae including joint damage and reduced …

Objectives Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may
improve treatment response; however, previous studies suggesting SDL cut-offs have not …

Objective Methotrexate (MTX) is effective in controlling disease activity in rheumatoid
arthritis (RA). Parenteral MTX may have benefits over oral MTX, but it is rarely used in …

This systematic literature review aimed to analyse terms describing coexisting conditions in
the RA literature, informing the need for an operationalized definition of multimorbidity …